Intrasense: Guerbet takes 39% of the capital and will launch a takeover bid for the company – 01/11/2023 at 6:30 p.m.


(AOF) – Intrasense, a specialist in medical imaging software solutions, announces the entry into its capital of the Guerbet group up to 39% through a reserved capital increase for a total amount of 8.8 million euros. euros at an issue price of 0.44 euro per share, ie a premium of 34.15% compared to Intrasense’s last share price. Guerbet plans to file soon, on a voluntary basis, a public tender offer for the balance of Intrasense shares, at a price of €0.44 per share, and for the securities giving access to the capital.

Nicolas Reymond, Managing Director of Intrasense declares that the presence of a reference shareholder within the capital will give his company the ability to penetrate its target markets “much more quickly and with better efficiency, thanks to an enriched offer and the optimization of (its) visibility within the global medical imaging ecosystem”. At the same time, the operation will allow Guerbet to ultimately develop its technology and its artificial intelligence algorithms.

As part of this project, Intrasense and Guerbet plan to enter into a license agreement in the first half of 2023 that would allow Intrasense to integrate and market Guerbet’s artificial intelligence algorithms within its software platforms, which would complement its various partnerships already concluded to date in oncology. A collaboration agreement has been in place since October 2022 to study the technical feasibility of this integration.

The agreement will allow Intrasense to integrate into its Myrian product offer as well as within its new line of oncology products the algorithms developed by Guerbet for the detection of liver lesions, prostate cancers, pancreatic cancers and bone lesions. Intrasense will be responsible for clinical validation and regulatory registration of products for which it will be the legal manufacturer.



Source link -86